Effect of hyperglycaemia and diabetes on acute myocardial ischaemia–reperfusion injury and cardioprotection by ischaemic conditioning protocols

DOI Web Site Web Site Web Site Web Site 被引用文献1件
  • Claudia Penna
    Department of Clinical and Biological Sciences University of Turin Turin Italy
  • Ioanna Andreadou
    Laboratory of Pharmacology, Faculty of Pharmacy National and Kapodistrian University of Athens Athens Greece
  • Manuela Aragno
    Department of Clinical and Biological Sciences University of Turin Turin Italy
  • Christophe Beauloye
    Division of Cardiology Cliniques Universitaires Saint‐Luc Brussels Belgium
  • Luc Bertrand
    Division of Cardiology Cliniques Universitaires Saint‐Luc Brussels Belgium
  • Antigone Lazou
    School of Biology Aristotle University of Thessaloniki Thessaloniki Greece
  • Ines Falcão‐Pires
    Unidade de Investigação Cardiovascular, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina Universidade do Porto Porto Portugal
  • Robert Bell
    The Hatter Cardiovascular Institute University College London London UK
  • Coert J. Zuurbier
    Laboratory of Experimental Intensive Care and Anesthesiology (L.E.I.C.A.), Department of Anesthesiology, Amsterdam UMC University of Amsterdam, Cardiovascular Sciences Amsterdam The Netherlands
  • Pasquale Pagliaro
    Department of Clinical and Biological Sciences University of Turin Turin Italy
  • Derek J. Hausenloy
    The Hatter Cardiovascular Institute University College London London UK

説明

<jats:sec><jats:label /><jats:p>Diabetic patients are at increased risk of developing coronary artery disease and experience worse clinical outcomes following acute myocardial infarction. Novel therapeutic strategies are required to protect the myocardium against the effects of acute ischaemia–reperfusion injury (IRI). These include one or more brief cycles of non‐lethal ischaemia and reperfusion prior to the ischaemic event (ischaemic preconditioning [IPC]) or at the onset of reperfusion (ischaemic postconditioning [IPost]) either to the heart or to extracardiac organs (remote ischaemic conditioning [RIC]). Studies suggest that the diabetic heart is resistant to cardioprotective strategies, although clinical evidence is lacking. We overview the available animal models of diabetes, investigating acute myocardial IRI and cardioprotection, experiments investigating the effects of hyperglycaemia on susceptibility to acute myocardial IRI, the response of the diabetic heart to cardioprotective strategies e.g. IPC, IPost and RIC. Finally we highlight the effects of anti‐hyperglycaemic agents on susceptibility to acute myocardial IRI and cardioprotection.</jats:p></jats:sec><jats:sec><jats:title>LINKED ARTICLES</jats:title><jats:p>This article is part of a themed issue on Risk factors, comorbidities, and comedications in cardioprotection. To view the other articles in this section visit <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.23/issuetoc">http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.23/issuetoc</jats:ext-link></jats:p></jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ